Yakira Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Yakira Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-74,056	Closed	-$1.71M	–	457
2020 Q4	$1.71M	Buy	+74,056	New	+$939K	0.41%	75

Yakira Capital Management's PRVL Position: Q1 2021 in Review

Yakira Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 74,056 shares — an estimated $1.71M sold.

Yakira Capital Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $1.71M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Yakira Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Yakira Capital Management sold 74,056 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $1.71M.
Yakira Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Yakira Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $1.71M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Yakira Capital Management's 13F filing for Q1 2021, filed 14 May 2021.